Clinical Research Directory
Browse clinical research sites, groups, and studies.
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Sponsor: University of Colorado, Denver
Summary
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
Official title: Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial
Key Details
Gender
All
Age Range
12 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-05-01
Completion Date
2031-04-30
Last Updated
2025-06-15
Healthy Volunteers
No
Conditions
Interventions
Semaglutide 1.7mg subcutaneous
Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
Placebo
Placebo saline solution subcutaneous
Locations (1)
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States